Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track AUPH with free AI briefings, catalyst countdowns, and dilution alerts.

AUPH · Aurinia Pharmaceuticals Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$443M Cash on Hand

CF+ Cash Runway

Follow AUPH by email Get an email when AUPH pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AUPH, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Mar 2029 · Phase 1/2 · Recruiting · Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Registry primary completion date, not a results date
Mar 2029 · Phase 4 · Recruiting · PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Voclosporin FDA approved Jan 2021 · Lupkynis	Lupus Nephritis	Phase 4 · NCT07611214	Recruiting
mycophenolic acid analog (MPAA)	Lupus Nephritis	Phase 4 · NCT07611214	Recruiting
Corticosteroid	Lupus Nephritis	Phase 4 · NCT07611214	Recruiting
0.10% VOS	Dry Eye Syndrome	Phase 2/3 · NCT04147650	Completed
Cyclosporine	Psoriasis	Phase 3 · NCT00408187	Completed
0.20% VOS	Dry Eye Syndrome	Phase 2/3 · NCT04147650	Completed
0.05% Voclosporin Ophthalmic Solution (V	Dry Eye Syndrome	Phase 2/3 · NCT04147650	Completed
Aritinercept	Myasthenia Gravis, Generalized	Phase 1/2 · NCT07596901	Recruiting
Voclosporin Ophthalmic Solution	Dry Eye	Phase 2 · NCT03597139	Completed

Also used in these trials (approved or third-party drugs, not AUPH's own candidates): Belimumab, Tacrolimus Extended-Release, Simvastatin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AUPH holds $443M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AUPH files for a raise →

👥 Who Owns AUPH

Insiders Form 4 data not loaded yet Other 5%+ holders 9.8% Institutions (378 holders) 60.5% Public and other holders 29.7%

Holder	Type	Shares	% of shares	As of
TANG CAPITAL MANAGEMENT, LLC	5%+ holder (13D)	13,044,106	9.80%	2026-06-02

Share count 133,051,168 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AUPH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AUPH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z